Table 2.
Results of the Kohonen SOM classifier (ns, not significant, *Kruskal–Wallis, **Tichý and Chytrý)
| Variables | Subcluster | Subcluster | Subcluster | Subcluster | P value |
|---|---|---|---|---|---|
| X1 | X2 | Y1 | Y2 | ||
| n (%) | n (%) | n (%) | n (%) | ||
| Total No of patients | 24 (23.0) | 28 (27.0) | 24 (23.0) | 28 (27.0) | |
| Mean age | 64 | 75.5 | 70.5 | 69 | |
| No female | 2 | 4 | 5 | 1 | |
| Grade | |||||
| G1 | 10 (41.7) | 13 (46.4) | 19 (79.2) | 18 (64.3) | <0.001* |
| G2-3 | 14 (58.3) | 15 (53.6) | 5 (12.5) | 10 (21.4) | |
| Stage | |||||
| Ta | 16 (66.7) | 15 (53.6) | 19 (79.2) | 20 (71.4) | ns* |
| T1 | 3 (12.5) | 8 (28.6) | 5 (20.8) | 5 (17.9) | |
| T2–T4 | 5 (20.8) | 5 (17.8) | 0 | 3 (10.7) | |
| Smoking history | |||||
| Current and ex | 24 (100) | 26 (92.9) | 22 (91.7) | 27 (96.4) | ns** |
| Never | 0 | 2 (7.1) | 2(8.3) | 1 (3.6) | |
| Occupational exp. | |||||
| Yes | 9 (37.5) | 9 (32.1) | 9 (37.5) | 12 (42.9) | ns** |
| No | 15 (62.5) | 19 (67.9) | 15 (62.5) | 16 (57.1) | |
| No of tumors | |||||
| 1 | 18 (75.0) | 18 (64.3) | 17 (63.0) | 21 (75.0) | ns* |
| >1 | 6 (25.0) | 10 (35.7) | 7 (37.0) | 7 (25.0) | |
| Tumor diameter | |||||
| 2 cm | 10 (41.7) | 7 (25.0) | 19 (79.2) | 18 (64.3) | <0.001* |
| >2 cm | 14 (58.3) | 21 (75.0) | 5 (20.8) | 10 (35.7) | |
| Local recurrence | |||||
| Yes | 5 (21.0) | 7 (25.0) | 7 (29.2) | 5 (17.9) | ns** |
| No | 19 (79.0) | 21 (75.0) | 17 (70.8) | 23 (82.1) | |
| HPV infection | |||||
| Yes | 4 (16.6) | 4 (14.3) | 3 (12.5) | 3 (10.7) | ns** |
| No | 20 (83.4) | 24 (85.7) | 21 (87.5) | 25 (89.3) | |
| CHEK2 mutation | |||||
| Yes | 2 (8.3) | 1 (3.6) | 1 (4.2) | 3 (10.7) | ns** |
| No | 22 (91.7) | 27 (96.4) | 23 (95.8) | 25 (89.3) | |
| FGFR3 mutation | |||||
| Yes | 1 (4.2) | 1 (3.6) | 9 (37.5) | 28 (100) | <0.001** |
| No | 23 (95.8) | 27 (96.4) | 15 (62.5) | 0 | |
| TP53 mutation | |||||
| Yes | 5 (20.8) | 5 (17.9) | 0 | 5 (17.9) | ns** |
| No | 19 (79.2) | 23 (82.1) | 24 (100) | 23 (82.10 | |
| TP53 expression | |||||
| Altered | 1 (4.2) | 16 (57.1) | 1 (4.2) | 11 (39.3) | <0.01** |
| Normal | 23 (95.8) | 12 (42.9) | 23 (95.8) | 17 (60.7) | |
| LOH chromosome 9 | |||||
| Yes | 1 (4.2) | 17 (60.7) | 7 (37.0) | 8 (28.6) | <0.001** |
| No | 23 (95.8) | 11 (39.3) | 17 (63.0) | 20 (71.4) | |
| LOH chromosome 13 | |||||
| Yes | 1 (4.2) | 3 (10.7) | 2 (8.3) | 0 | ns** |
| No | 23 (95.8) | 25 (89.3) | 22 (91.7) | 28 (100) | |
| LOH chromosome 17 | |||||
| Yes | 2 (8.3) | 8 (28.6) | 0 | 2 (7.1) | <0.01** |
| No | 22 (91.7) | 20 (71.4) | 24 (100) | 26 (92.9) | |
| UroVysion test | |||||
| Positive | 24 (100) | 26 (92.9) | 0 | 24 (85.7) | <0.001** |
| Negative | 0 | 2 (7.1) | 24 (100) | 4 (14.3) | |
| CDKN2A polymorphism | |||||
| Ala/Thr | 5 (20.8) | 1 (3.6) | 1 (4.2) | 0 | <0.05** |
| Ala/Ala | 19 (79.2) | 27 (96.4) | 23 (95.8) | 28 (100) | |
| CYP1B1 polymorphism | |||||
| 355T/T | 5 (20.8) | 3 (10.7) | 1 (4.2) | 5 (17.9) | ns** |
| 355T/T and T/G | 19 (79.2) | 25 (89.3) | 23 (95.8) | 23 (82.1) | |
| TP53 polymorphism | |||||
| Arg | 16 (66.6) | 15 (53.6) | 13 (54.2) | 11 (39.3) | ns** |
| Arg/Pro | 7 (29.2) | 12 (42.9) | 9 (37.5) | 13 (46.4) | |
| Pro | 1 (4.2) | 1 (3.5) | 2 (8.3) | 4 (14.3) | |